Honored to be presenting at #DDW2023 along with my esteem co-presenters Drs. Hirano, Pham, @MFeelyDO@AKE_Path @DocStanich, with our wonderful moderator @DiptiKaramchan2 at Session: AGA Key to Optimal Patient Care: Good Clinician-Pathologist Communication. @USGIPS@DDWMeeting
Started 2nd EUS-chemoablation expanded access protocol (EAP) with LSAM-PTX (Sub-micronized Paclitaxel) for BD-IPMNs.
Encouraging data from preceding (1st) EAP
N=6 BD-IPMNs
50-90% ⏬ volume
31-80% ⏬ surface area
Loss of pathogenic mutations-83%
Fibrosis & calcification-83%
After 6 months of clearing all regulatory issues - excited to start our prospective study evaluating EUS-RFA in the management of BD-IPMNs.
The ERASE study (E⃣US-guided R⃣FA of PCLs - A⃣ S⃣afety & E⃣fficacy trial)
Pre-trial case (below) with a great response.
EUS-guided chemoablation with LSAM-PTX (NanoPac). Excellent resolution of a 4cm BD-IPMN.
Immediate & a year later - continued durable response.
Confident ablation > possible with a highly accurate diagnosis of cysts by EUS-endomicroscopy (nCLE) & fluid molecular analysis (NGS)
You know how you’ve always wanted to live in FL and dream of working with awesome folks like @DHGGIpath and @XiuliLiu1? Now’s your chance! We have an unexpected opening in our GI liver fellowship for 2020. See link. #GIpath#pathology
https://t.co/FndbupW7AY
First it was the CAP abstract book and now this! It has been a good year for cover photos. @PediDevPath Thank you for the selection! Article on Sclerosing Epithelioid Fibrosarcoma of Bone with EWSR1-CREB3L3 fusion here: https://t.co/PvRhjl2SZp #pedipath@SocPediPath@LeaSurrey